Next Generation Flexible and Cognitive Heterogeneous Optical Networks:Supporting the Evolution to the Future Internet

Optical networking is the cornerstone of the Future Internet as it provides the physical infrastructure of the core backbone networks. Recent developments have enabled much better quality of service/experience for the end users, enabled through the much higher capacities that can be supported. Furthermore, optical networking developments facilitate the reduction of complexity of operations at the IP layer and therefore reduce the latency of the connections and the expenditures to deploy and operate the networks. New research directions in optical networking promise to further advance the capabilities of the Future Internet. In this book chapter, we highlight the latest activities of the optical networking community and in particular what has been the focus of EU funded research. The concepts of flexible and cognitive optical networks are introduced and their key expected benefits are highlighted. The overall framework envisioned for the future cognitive flexible optical networks are introduced and recent developments are presented

Desert dust outbreak in the Canary Islands (February 2020): assessment and impacts

World Weather Research Programme (WWRP 2021–1

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective